<DOC>
	<DOCNO>NCT00892931</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness Azixa patient recurrent glioblastoma multiforme</brief_summary>
	<brief_title>Phase 2 Study MPC-6827 Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Have histologically proven malignant Glioblastoma Multiforme first second relapse Have fail prior Fractionated External Beam Cranial Irradiation IMRT Be least 18 year old life expectancy ≥ 8 week ≥ 4 week fail prior Avastin therapy Have Karnofsky performance status ≥ 60 Have adequate bone marrow function , liver function , renal function start therapy Have two relapse Have radiosurgery Have cardiac ejection fraction &lt; 50 % MUGA ECHO Have TroponinI elevate normal range Have increase steroid requirement Have MRI evidence baseline enlarge clinically significant intratumor hemorrhage Have active stroke and/or transient ischemic attack optimally manage Have active cardiovascular disease ( e.g . suboptimally manage angina , impend myocardial infarction , uncontrolled hypertension ) Be pregnant breast feeding Have prior hypersensitivity reaction Cremophor EL Be HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Brain Neoplasms</keyword>
	<keyword>Recurrence</keyword>
</DOC>